Proficiency testing (PT) is a critical quality assurance tool that ensures laboratory accuracy and reliability by comparing test results with established standards. Improper handling of PT—especially through unauthorized referral to external labs—can lead to regulatory sanctions, making it essential for lab directors, supervisors, and staff to understand and comply with PT referral rules.

Dr. Bill Morice shares how clinical diagnostics are expanding to guide treatment and enable clinicians to target therapies more precisely.

Accurate coagulation testing starts with proper specimen preparation. Even small pre-analytic errors, such as underfilled tubes, hemolysis, or improper centrifugation, can compromise results and patient care.

After mysterious neurological symptoms began in 2010, Brad Karon, M.D., Ph.D., was diagnosed with paraneoplastic syndrome, a rare condition that led to groundbreaking research and test development at Mayo Clinic. Years later, pulmonary fibrosis and a double lung transplant would test him once again — and redefine his resilience.

This episode marks the end of “Lab Medicine Rounds.” Host Justin Kreuter, M.D., reflects on the impact of the series and introduces an upcoming video-based[...]

In this episode of “Answers From the Lab,” host Bobbi Pritt, M.D., chair of the Division of Clinical Microbiology at Mayo Clinic, and William Morice II, M.D., Ph.D., CEO and president of Mayo Clinic Laboratories, discuss summertime illnesses and key insights from a recent diagnostic investment event.

Linda Hasadsri, M.D., Ph.D., and Huong Cabral, M.S., CGC, explain how Mayo Clinic Laboratories' expanded test panel captures rarer as well as more common genetic causes of hereditary pancreatitis. That information is key to managing patients' enhanced risk for pancreatic cancer.

Join us for Mayo Clinic Laboratories Education first-ever virtual phlebotomy workshop on Wednesday, Oct. 1.

PACE/State of FL - Presentation Recording Coming Soon - This presentation explores the distinctions between capillary and venous collection and compares home-based versus clinic-based sampling, with attention to delayed processing and shipping stability. 

Clinically relevant overview of key genetic factors, testing strategies, and post-result care.

Conflict is a natural part of human interaction, and the workplace is not immune from that experience.  Through this microlearning, we'll explore how proper conflict[...]

In this episode of “Answers From the Lab,” host Bobbi Pritt, M.D., chair of the Division of Clinical Microbiology at Mayo Clinic, and William Morice II, M.D., Ph.D., CEO and president of Mayo Clinic Laboratories, share insights from industry news and recent conferences, including PlatforMed.

Joshua Bornhorst, Ph.D., explains how Mayo Clinic Laboratories' labile copper assay (Mayo ID: LBCS) improves upon standard blood tests for Wilson's disease. The new assay measures not just overall copper but also the fraction of copper that is bioavailable, or labile bound.

For healthcare professionals seeking to enhance their understanding of the assessment and treatment options for patients with neurodegenerative diseases.

In this episode of Mayo Clinic Laboratories’ “Leveraging the Laboratory” podcast, host Jane Hermansen, outreach manager at Mayo Clinic Laboratories, is joined by colleagues Ellen Dijkman Dulkes and Brianne Newton. They discuss common reasons that outreach programs fail to launch and strategies for building momentum to implement a program.